A chemically stabilized (stapled) version of cone snail venom peptide conantokin-G blocked NMDA receptors (IC50=0.7 μM) and protected against drug-resistant epilepsy in mice without causing motor toxicity seen with the natural peptide.
IC50 = 0.7 μM with no motor toxicityThe stapled conantokin analog potently blocked NR2B NMDA receptors and protected against drug-resistant seizures in mice — but unlike the natural cone snail peptide, it caused no behavioral motor toxicity, demonstrating how peptide engineering can eliminate deal-breaking side effects.
What the researchers found
The stapled conantokin-G analog conG[11-15,S(i,i+4)S(8)] demonstrated:
- Potent NR2B-selective NMDA receptor antagonism: IC50 = 0.7 μM
- Significant protection in the 6-Hz psychomotor seizure model (a model specifically designed to detect efficacy against drug-resistant epilepsy)
- No behavioral motor toxicity (unlike native conantokin-G)
- Enhanced helical conformation in metal-free environments (confirmed by circular dichroism and molecular modeling)
- NMR confirmed single Z-configuration olefinic bond from ring-closing metathesis
The i,i+4 staple positioning successfully replaced the γ-carboxyglutamic acid residues' metal-chelation function while preserving pharmacological activity.
Why it matters
About one-third of epilepsy patients don't respond to existing medications — this is called pharmacoresistant or drug-resistant epilepsy. NMDA receptor antagonists, particularly NR2B-selective ones, are promising for these patients but have been plagued by side effects. This study shows that peptide stapling can transform a natural venom peptide into a drug candidate that is effective in a drug-resistant epilepsy model while eliminating the motor side effects that would otherwise prevent clinical use.
How the study worked
Multiple stapled analogs of conantokin-G were designed with varying staple lengths and positions along the α-helix. Peptides were synthesized using ring-closing metathesis. Structural characterization included NMR spectroscopy, circular dichroism, and molecular modeling. In vitro activity was tested in NMDA receptor antagonism assays (NR2B-containing receptors). In vivo efficacy was assessed in the 6-Hz psychomotor seizure model in mice (a validated model of pharmacoresistant epilepsy). Motor toxicity was evaluated by behavioral assessment.
What this study cannot tell us
Preclinical mouse study — efficacy and safety in humans are unknown. The 6-Hz seizure model, while specifically designed for drug-resistant epilepsy, does not capture all forms of human epilepsy. Only one stapled analog showed the ideal profile (efficacy without toxicity), suggesting the optimization window is narrow. Pharmacokinetics, brain penetration, and metabolic stability were not reported. The peptide requires synthesis by ring-closing metathesis, which may pose manufacturing challenges at scale. The study is from 2012 and follow-up clinical development status is unclear.
How to read the evidence
This is a preclinical study combining peptide chemistry, in vitro pharmacology, and in vivo mouse seizure models. The 6-Hz model is specifically designed to detect efficacy against drug-resistant epilepsy, adding clinical relevance. However, all data are from mice, and the study does not address clinical pharmacokinetics or human safety.
When this study was published
Published in 2012, this study is over a decade old. While the stapled peptide technology has advanced significantly since then, the specific application to conantokins for epilepsy may not have been extensively followed up. The fundamental principles of peptide stapling demonstrated here remain highly relevant.
The bigger picture
Peptide stapling is one of the most exciting developments in peptide drug design, enabling researchers to lock peptides into their bioactive conformations for improved stability and pharmacology. This study is one of the first to apply stapling to venom-derived peptides with extracellular targets (most stapled peptide work had been on intracellular targets). The success in eliminating motor toxicity while preserving anti-seizure efficacy demonstrates the power of peptide engineering to overcome fundamental limitations of natural toxin-derived drug candidates.
Questions still open
- Has the stapled conantokin-G analog progressed toward clinical trials for drug-resistant epilepsy?
- Can the stapling approach be applied to other conotoxin peptides to create new therapeutics for pain, cardiovascular, or neurological conditions?
- What are the pharmacokinetics and brain penetration of the stapled analog, and can it be administered systemically?
Common questions
What is peptide stapling and why does it matter?
Could cone snail venom peptides treat epilepsy?
Read the original research
Stapling mimics noncovalent interactions of γ-carboxyglutamates in conantokins, peptidic antagonists of N-methyl-D-aspartic acid receptors.
The Journal of biological chemistry, 287(24), 20727-36
Citation
Platt, Randall J; Han, Tiffany S; Green, Brad R; Smith, Misty D; Skalicky, Jack; Gruszczynski, Pawel; White, H Steve; Olivera, Baldomero; Bulaj, Grzegorz; Gajewiak, Joanna. (2012). Stapling mimics noncovalent interactions of γ-carboxyglutamates in conantokins, peptidic antagonists of N-methyl-D-aspartic acid receptors.. The Journal of biological chemistry, 287(24), 20727-36. https://doi.org/10.1074/jbc.M112.350462